This review summarises and discusses the key efficacy and safety outcomes from the first head-to-head clinical
comparison of two second-generation basal insulin analogues in the treatment of insulin-naïve patients with
uncontrolled type 2 diabetes.
Expert independent commentary provided by Dr Richard Simpson, former Director of Diabetes &
Endocrinology at Box Hill Hospital and Assoc. Professor of Medicine, Monash University and Dr Alice Cheng who is a member of the Division of Endocrinology and Metabolism at Trillium Health Partners and St. Michael’s Hospital in Toronto, Canada and is an Associate Professor in the Department of Medicine at the University of Toronto.
Please login below to download this issue (PDF)